Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT: Olaparib in Relapsed Ovarian Cancer
NCT02983799Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate up to 36 months. Started Dec 2016; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02983799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983799.